Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Not refereed |
Title | Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. |
Journal | Formal name:Journal of gastroenterology Abbreviation:J Gastroenterol ISSN code:1435-5922(Electronic)0944-1174(Linking) |
Domestic / Foregin | Foregin |
Volume, Number, Page | 52(9),pp.1031-40 |
Papers・Author | Suzuki Yasuo, Motoya Satoshi, Hanai Hiroyuki, Hibi Toshifumi, Nakamura Shiro, Lazar Andreas, Robinson Anne Martin, Skup Martha, Mostafa Nael Mohamed, Huang Bidan, Thakkar Roopal, Watanabe Mamoru |
Publication date | 2017/09 |
Papers・Description | BACKGROUND:The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented.METHODS:Remission and response per the full Mayo score (FMS) and the partial Mayo score (PMS), remission per the Inflammatory Bowel Disease Questionnaire (IBDQ) score, corticosteroid-free remission, and mucosal healing were assessed up to week 196 (week 208 for remission/response per PMS) of adalimumab treatment in patients who received one or more doses of adalimumab with use of a hybrid nonresponder imputation (hNRI) method. |
DOI | 10.1007/s00535-017-1325-2 |
PMID | 28321512 |